Abivax (ABVX) Return on Capital Employed (2025 - 2026)
Abivax (ABVX) posted quarterly Return on Capital Employed of 50.43% for Q1 2026, up 16829.0% year-over-year from N/an in Q1 2025, and down 16.64% quarter-over-quarter from 43.23% in Q4 2025.
Abivax (ABVX) Return on Capital Employed (2025 - 2026) Analysis & Trends
Abivax's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 50.43% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 16829.0% year-over-year to 50.43%; the TTM figure through Mar 2026 stood at 50.43% (up 16829.0% YoY), while the FY2025 annual figure was 76.11%, up 2374.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 50.43%, down from 43.23% in the prior quarter.
- The five-year high for Return on Capital Employed was 43.23% in Q4 2025, with the low at 716.91% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -50.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.43% |
| Dec 31, 2025 | -43.23% |
| Sep 30, 2025 | -67.94% |
| Jun 30, 2025 | -716.91% |
| Mar 31, 2025 | -218.72% |